Summer Sale
Up to 30% off — ends 2 Aug
ONLY00h00m00s
Up to 30% off — ends 2 Aug
ONLY00h00m00s
Steve Jackson
Top university
10 months ago
This position has expired. You can find similar positions from the section below or browse our positions listing pages.
Cancer research and radiation therapy University of Cambridge in United Kingdom
Degree Level
PhD
Field of study
Biomarker Research
Funding
Full funding availableDeadline
Oct 1, 2026
Country
United Kingdom
University
University of Cambridge

How do I apply for this?
Sign in for free to reveal details, requirements, and source links.
Suggested positions
Keywords
Biomarker Research
Cancer Biology
Biology
Radiation Therapy
Health Science
Dna Damage
Crispr/cas9
About this position
Funding details
Full funding including tuition fees and living expenses is available for this position. The scholarship covers all educational costs and provides a monthly stipend.
Ask ApplyKite AI
Start chatting
Can you summarize this position?
What qualifications are required for this position?
How should I prepare my application?
Professors

How do I apply for this?
Sign in for free to reveal details, requirements, and source links.
University of Cambridge - Cancer Research UK Cambridge Institute (CRUK CI) and the AstraZeneca Discovery Centre
Supervisors: Professor Sir Steve Jackson and Dr Mark O'Connor (AZ Partner)
Course start date: 1st October 2026
Funding: Funding includes a stipend for four years, tuition fees (at Home rate only) and an allocation towards project consumables and training.
Eligibility: Applicants with relevant research experience are strongly encouraged to apply.
The position is open to UK citizens, or overseas students meeting the UK residency requirements, or able to cover the difference in international fees through additional funding awards.
Project details
Targeted Alpha Therapy (TAT) selectively delivers high Linear Energy Transfer (LET) alpha-particles to cancer cells, maximising efficacy while minimising toxicity. Knowledge about radiation sensitivity, accrued mainly with sparsely ionising low-LET radiation (e.g. X-ray, -ray), demonstrated that genetic backgrounds influence radiation therapy (RT) responses, with DNA-damage response (DDR) pathways critically involved. However, determinants of sensitivity to high-LET radiation, such as alpha particles emitted by TAT, remain largely unexplored.
Emerging data suggest that some cancer cells within the alpha particle emission path only receive sub-lethal levels of DNA damage and can survive. Combining TAT and DDR inhibitors thus has the potential to convert this sub-lethal DNA damage into cancer cell killing.
This project will explore the effects of radioligand therapies on cell viability and DDR activation in established human cell models. The student will perform CRISPR screens to determine factors that affect resistance/sensitivity and follow these up with mechanistic studies of a shortlist of identified targets. These studies may uncover mechanisms of cellular responses, potential biomarkers and additional therapeutic vulnerabilities that underlie the responses of normal and tumour cells to alpha radiotherapy.
Apply here: https://lnkd.in/eGCVMtC3
# ChangingtheNarrative